Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance combination umbrella study in advanced or metastatic urothelial carcinoma
2021-003669-36Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) and bladder cancer comparing Avelumab monotherapy maintenance, Avelumab + sacituzumab govitecan maintenance and Avelumab + aviptadil pegol maintenance (3 arms). Primary endpoint: Progression-free survival. Started Apr 2022; status: active.
02
Drugs
avelumabsacituzumab govitecanNKTR-255
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2021-003669-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003669-36.